The FDA on August 8, 2018 approved POTELIGEO® for adult patients with Relapsed or Refractory Mycosis Fungoides (MF) or Sézary Syndrome (SS) after at least one prior systemic therapy. POTELIGEO® is a product of Kyowa Kirin, Inc.
Other Pages – Top Ad
Advertisement